|Bid||3.7600 x 1000|
|Ask||3.8900 x 1200|
|Day's Range||3.5800 - 3.8700|
|52 Week Range||1.6000 - 6.4700|
|Beta (5Y Monthly)||1.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.71|
The big shareholder groups in Aptinyx Inc. (NASDAQ:APTX) have power over the company. Generally speaking, as a company...
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2020 and highlighted recent progress across the company’s clinical-stage pipeline of novel NMDA receptor modulators.
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Aptinyx, Inc.